Concepedia

Matthew Stefanovski

MS

5

Publications

1.1K

Citations

5

H-Index

2012

Active since

Affiliations

The Ohio State University(Current)

Pharmacyclics (United States)

Matthew Stefanovski is an author at The Ohio State University specializing in medicine, tumor immunity, and immunotherapy.

Top concepts

Publications per year

2012–2014

5

Publications

5

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan et al. · Blood · 2013 · 783 citations · Full text

Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)

Jennifer A. Woyach, Engin Bojnik, Amy S. Ruppert et al. · Blood · 2013 · 213 citations · Full text

The CD37-targeted antibody–drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model

Kyle A. Beckwith, Frank Frissora, Matthew Stefanovski et al. · Leukemia · 2014 · 39 citations · Full text

, , +8

Pharmacokinetics and Tissue Disposition of Lenalidomide in Mice

Darlene M. Rozewski, Sarah E.M. Herman, William H. Towns et al. · The AAPS Journal · 2012 · 34 citations · Full text

, , +3

Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies

Yicheng Mao, Georgia Triantafillou, Erin Hertlein et al. · Clinical Cancer Research · 2012 · 34 citations · Full text

Rows per page

1–5 of 5